ReviewCancers2023
Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07613151 (NAPOLI), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NAPOLI: Negative/Low Hormone Receptor and APOcrine Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Omission of Axillary Surgery in Patients with Invasive Lobular Carcinoma of the Breast: Rates of Nodal Involvement in Clinically Node Negative Patients and Impact on Recurrence in a Single Institution Analysis.Annals of surgical oncology · 2026Article
- Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Molecules (Basel, Switzerland) · 2026Review
- Axillary Nodal Positivity in Early-Stage Invasive Lobular Carcinoma: Implications for Sentinel Lymph Node Biopsy Omission.Annals of surgical oncology · 2026Article
- Contrast-Enhanced Mammography and Deep Learning-Derived Malignancy Scoring in Breast Cancer Molecular Subtype Assessment.Medicina (Kaunas, Lithuania) · 2026Article
- Rare overlap of subtype and phenotype: HER2-positive pleomorphic invasive lobular carcinoma presenting with an inflammatory breast cancer phenotype: a case report and targeted treatment strategy.Frontiers in oncology · 2026Article
- Carcinoma en cuirasse mimicking dermatomal herpes zoster: A case report.SAGE open medical case reports · 2026Article
- Examining a Genomic Test in Predicting Extended Endocrine Benefit and Recurrence Risk in a Diverse Breast Cancer Population.Current oncology (Toronto, Ont.) · 2025Article
- Radiation therapy for lobular breast cancer: opportunities and challenges for leveraging radiosensitivity.NPJ breast cancer · 2025Review
- Diagnosis and Management of Invasive Pleomorphic Lobular Carcinoma of the Breast: A Case Report and Comprehensive Review of Current Literature.Cancer reports (Hoboken, N.J.) · 2025Review
- Nuclear morphological characterisation of lobular carcinoma variants: a morphometric study.Histopathology · 2025Article
- E-cadherin staining in the diagnosis of lobular versus ductal neoplasms of the breast: the emperor has no clothes.Histopathology · 2025Review
- Molecular Basis of Breast Tumor Heterogeneity.Advances in experimental medicine and biology · 2025Review
- Article
- Nomograms to predict the long-term prognosis for non-metastatic invasive lobular breast carcinoma: a population-based study.Scientific reports · 2024Article
- Deciphering the Clinical Behaviour of Invasive Lobular Carcinoma of the Breast Defines an Aggressive Subtype.Cancers · 2024Article
- Early Stage Breast Cancer: Does Histologic Subtype (Ductal vs. Lobular) Impact 5 Year Overall Survival?Cancers · 2024Article
- Case report: Unusual breast cancer metastasis manifesting as a scalp lesion in a patient with invasive lobular carcinoma.Frontiers in oncology · 2024Article
- Rectal Metastasis from Breast Cancer: A Case Report and Review of Literature.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The second most common breast carcinoma, invasive lobular carcinoma, accounts for approximately 15% of tumors of breast origin. Its incidence has increased in recent times due in part to hormone replacement therapy and improvement in diagnostic modalities. Although believed to arise from the same cell type as their ductal counterpart, invasive lobular carcinomas (ILCs) are a distinct entity with different regulating genetic pathways, characteristic histologies, and different biology. The features most unique to lobular carcinomas include loss of E-Cadherin leading to discohesion and formation of a characteristic single file pattern on histology. Because most of these tumors exhibit estrogen receptor positivity and Her2 neu negativity, endocrine therapy has predominated to treat these tumors. However novel treatments like CDK4/6 inhibitors have shown importance and antibody drug conjugates may be instrumental considering newer categories of Her 2 Low breast tumors. In this narrative review, we explore multiple pathological aspects and translational features of this unique entity. In addition, due to advancement in technologies like spatial transcriptomics and other hi-plex technologies, we have tried to enlist upon the characteristics of the tumor microenvironment and the latest associated findings to better understand the new prospective therapeutic options in the current era of personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.